For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).

Taking GLP-1 RAs is associated with fewer hospitalizations overall and less need for medications used to stop and prevent ...

Explore the benefits of the Precision GLP-1 agonist, a new therapy that improves glycaemic control and reduces side effects.

The researchers found that GLP-1 RA use was associated with significantly lower odds of vertebral compression fractures compared with nonuse. (HealthDay News) — Glucagon-like peptide 1 receptor ...

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

GLP-1 receptor agonists may reduce glaucoma risk in T2D patients, though the reduction was nonsignificant. The review included five high-quality observational studies with over 2.5 million ...

The use of GLP-1 receptor agonists (GLP-1 RAs) was associated with a lower risk for serious infections — particularly respiratory, skin and soft tissue, musculoskeletal, and vascular infections as ...

Retrospective cohorts show GLP-1 RA exposure yields ~5% relative weight reduction and an apparent OS advantage, while ...

Glucagon-like peptide-1 receptor agonist therapy with liraglutide or semaglutide is not associated with an increased risk for thyroid cancer among patients with type 2 diabetes or obesity, according ...